Maximizing the therapeutic potential of enzyme replacement therapy for lysosomal storage diseases

Editorial

V Gieselmann. Int J Clin Pharmacol Ther. 2009 Dec.

. 2009 Dec;47(12):707-8.

doi: 10.5414/cpp47707.

No abstract available

Similar articles

LSDs and the immune system.
Beck M, Vanier M. Beck M, et al. Int J Clin Pharmacol Ther. 2009;47 Suppl 1:S85. doi: 10.5414/cpp47085. Int J Clin Pharmacol Ther. 2009. PMID: 20040317 No abstract available.
Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction.
Kishnani PS, Dickson PI, Muldowney L, Lee JJ, Rosenberg A, Abichandani R, Bluestone JA, Burton BK, Dewey M, Freitas A, Gavin D, Griebel D, Hogan M, Holland S, Tanpaiboon P, Turka LA, Utz JJ, Wang YM, Whitley CB, Kazi ZB, Pariser AR. Kishnani PS, et al. Mol Genet Metab. 2016 Feb;117(2):66-83. doi: 10.1016/j.ymgme.2015.11.001. Epub 2015 Nov 10. Mol Genet Metab. 2016. PMID: 26597321 Review.
Regulatory watch: enhanced chance of success for protein replacement therapies.
Crunkhorn S. Crunkhorn S. Nat Rev Drug Discov. 2013 Jun;12(6):414. doi: 10.1038/nrd4027. Nat Rev Drug Discov. 2013. PMID: 23722335 No abstract available.
The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders.
Broomfield A, Jones SA, Hughes SM, Bigger BW. Broomfield A, et al. J Inherit Metab Dis. 2016 Jul;39(4):499-512. doi: 10.1007/s10545-016-9917-1. Epub 2016 Feb 16. J Inherit Metab Dis. 2016. PMID: 26883220 Review.
Perspectives from B cell immunology: fact and fancy.
Hunt SV. Hunt SV. Int J Clin Pharmacol Ther. 2009;47 Suppl 1:S86-99. doi: 10.5414/cpp47086. Int J Clin Pharmacol Ther. 2009. PMID: 20040318 Review.